Hiroki Umehara

Company: Sumitomo Pharma

Job title: Senior Director

Seminars:

Combining CHK1 Inhibitor with Nano Medicine Technology to Reduce Toxicity in Solid Tumor Targeting 4:30 pm

Discussing how CHK1 inhibitors target the DNA damage response by preventing cell cycle arrest and DNA repair in cancer cells, leading to apoptosis under conditions of high replication stress Exploring the role of liposomal encapsulation in modifying the pharmacokinetics of CHK1 inhibitors, such as SMP-3124, to enhance anti-tumor activity and reduce systemic toxicity Assessing the…Read more

day: Day One